Cellceutix Corporation, a clinical stage biotechnology company, focuses on discovering small molecule drugs for hard to treat diseases, including drug-resistant cancers, psoriasis, autism and inflammatory disease. Products Brilacidin; The intravenous formulation of Brilacidin has the potential to treat various indications, including Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by either drug-sensitive or drug-resistant strains of Staphylococcus aureus bacteria. The company has completed enrollment of 215 patients in a Phase 2b clinical trial for ABSSSI. Kevetrin: The company’s main cancer compound, Kevetrin, is in its ninth cohort in a Phase 1 clinical trial at Harvard Cancer Center's Dana-Farber Cancer Institute and partner Beth Israel Deaconess Medical Center, testing Kevetrin against advanced solid tumors. The company has conducted pre-clinical studies in lung cancer, head and neck cancer, colon cancer, breast cancer, prostate cancer, pancreatic cancer and in leukemia models. Prurisol: In 2012, the company participated in a pre investigational new drug application meeting with the U.S. Food and Drug Administration (FDA) pertaining to Prurisol its compound targeting psoriasis. Delparantag: Delparantag is a synthetic, small-molecule intended to reverse the effects of the commonly used anticoagulants unfractionated heparin (UFH), and its derivatives, low molecular weight heparins (LMWH), to help manage the balance of antithrombosis and anticoagulation and reduce the incidence of bleeding in certain interventional cardiology procedures, such as Percutaneous Coronary Intervention (PCI) and Coronary Arterial Bypass Grafting (CABG), and other situations where UFH and LMWH are used and bleeding may occur. The company is evaluating this drug for other diseases, including Chronic Obstructive Pulmonary Disease (COPD). Strategy The company’s strategy is to use its business and scientific expertise to maximize the value of diverse pipeline. Regulations The Federal Food, Drug and Cosmetic Act, and other federal and state statutes and regulations, govern the testing, manufacture, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion of the company’s products. Intellectual Property The company has trademark protection for the marks PolyMedix, PolyCide, and PolyDentix. The company has been assigned all right title and interest to the following eight pharmaceutical compounds: Kevetrin; KM 277; KM 278; Prurisol; KM 362; KM 3174; KM 732; and KM-391. Significant Events In September 2013, the company purchased substantially all of the assets of Polymedix Inc, and Polymedix Pharmaceuticals, Inc. from the U.S. Bankruptcy Court. PolyMedix Inc. was founded based on technology licensed from the University of Pennsylvania. History Cellceutix Corporation was founded in 2007.
cellceutix corp (CTIX:OTC US)
100 Cumming Center
Beverly, MA 01915
|No competitor information is available for CTIX.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact CELLCEUTIX CORP, please visit www.cellceutix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.